Seroxo
Biotechnology Research • 
London, England, United Kingdom • 1-10 Employees
Company overview
| Headquarters | London, England, United Kingdom |
| Website | |
| NAICS | 541714 |
| Founded | 2020 |
| Employees | 1-10 |
Key Contact at Seroxo
David Sarphie
Co-Founder and CEO
About Seroxo
Seroxo is a clinical-stage IVD company developing a proprietary point-of-care (POC) platform technology that enables rapid measurement of Immune Dysfunction, with applications in sepsis, cancer, and organ transplantation. With a clinical data package from 10x clinical trials in over 600 patients, Seroxo has demonstrated the superior performance and clinical benefit of its proprietary biomarker over competing biomarkers. Seroxo anticipates multiple licensing opportunities. The Leukocyte ImmunoTest™ (LIT™), Seroxo’s finger-prick POC blood test assesses real-time neutrophil function through a patented 10-minute assay that has been shown to be superior to current biomarkers for a range of clinical applications, including sepsis, cancer, and organ perfusion/transplantation. Both clinical and home-use tests will be developed and launched in multiple territories worldwide.
Seroxo revenue & valuation
| Annual revenue | $342,220 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,100,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Seroxo has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Seroxo has never raised funding before.
Saudi Arabia
United States
Australia
CanadaFrequently asked questions
4.8
40,000 users
